Kairos Pharma to Showcase KROS 101 Immunotherapy Research at 2025 ASCO Annual Meeting

Kairos Pharma will present new research on its experimental cancer immunotherapy candidate KROS 101 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, scheduled for June 2 at McCormick Place in Chicago, will focus on the drug's potential to enhance T cell function and improve cancer treatment strategies.

The poster, titled "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," represents a significant opportunity to explore innovative approaches to cancer immunotherapy. By targeting the GITR ligand, researchers aim to understand how KROS 101 might modulate immune system responses within tumor environments.

Kairos Pharma, a Los Angeles-based oncology therapeutics company, continues to leverage structural biology to address critical challenges in cancer treatment. The company's research focuses on overcoming drug resistance and immune suppression, which are significant obstacles in current cancer therapies.

While KROS 101 is being highlighted at this conference, the company is simultaneously advancing another promising candidate, ENV105, which targets CD105 - a protein associated with treatment resistance. ENV105 is currently in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.

The ASCO Annual Meeting presentation represents an important step in understanding how targeted molecular approaches might revolutionize cancer treatment by enhancing the body's immune response and potentially improving patient outcomes.